Melfalan Tillomed

Melphalan, the active ingredient in Melfalan Tillomed, is an alkylating agent presented as a sterile intravenous solution for intravenous use. It treats multiple myeloma, ovarian cancer and malignant melanoma in adult patients.

GNH USA supplies Melfalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melfalan Tillomed is an alkylating chemotherapy used in hematologic and solid‑tumor malignancies.

Multiple myeloma: improves disease control and prolongs survival in eligible patients. Ovarian cancer: incorporated into combination regimens to reduce tumor burden. Malignant melanoma: employed in advanced disease to achieve tumor regression.

Melfalan Tillomed may cause a range of adverse reactions during treatment.

Common Side Effects: - Nausea and vomiting - Bone‑marrow suppression leading to anemia or neutropenia - Alopecia (hair loss) - Fatigue and general weakness

Serious or Rare Side Effects: - Secondary malignancies such as therapy‑related leukemia - Severe infections due to profound immunosuppression - Pulmonary toxicity including interstitial pneumonitis - Renal impairment or electrolyte disturbances - Anaphylactic or severe hypersensitivity reactions

Prior to initiating therapy, clinicians should assess baseline organ function and monitor patients closely.

Monitor blood counts: perform regular complete blood count assessments. Assess renal function: evaluate serum creatinine and adjust dosing if needed. Evaluate hepatic function: check liver enzymes before and during treatment. Avoid use in patients with known hypersensitivity to melphalan or related alkylating agents. Use effective contraception: advise both male and female patients to use reliable birth control during and after therapy. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Melphalan can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other alkylating agents may increase myelosuppression. - Live vaccines should be avoided because of immunosuppression risk. - High‑dose radiation therapy can exacerbate tissue toxicity.

Moderate Interactions (Monitor Closely): - Antiemetic agents (e.g., ondansetron) may require dose adjustment for optimal control of nausea. - Antifungal azoles can affect hepatic metabolism and should be monitored. - Non‑steroidal anti‑inflammatory drugs may increase risk of renal impairment when combined with melphalan.